References
1. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et
al. Tisagenlecleucel in Children and Young Adults with B-Cell
Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439-48.
2. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et
al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic
Toxicity Associated with Immune Effector Cells. Biol Blood Marrow
Transplant. 2019;25(4):625-38.
3. Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, et al.
Hematopoietic recovery in patients receiving chimeric antigen receptor
T-cell therapy for hematologic malignancies. Blood Adv.
2020;4(15):3776-87.
4. Juluri KR, Wu QV, Voutsinas J, Hou J, Hirayama AV, Mullane E, et al.
Severe cytokine release syndrome is associated with hematologic toxicity
following CD19 CAR T-cell therapy. Blood Adv. 2022;6(7):2055-68.
5. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T
cells: recognition and management. Blood. 2016;127(26):3321-30.
6. Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, et al.
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in
relapsed/refractory large B-cell lymphoma. Blood. 2021;138(24):2499-513.
7. Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, et
al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone
Marrow Transplant. 2019;54(10):1643-50.
8. Luo W, Li C, Zhang Y, Du M, Kou H, Lu C, et al. Adverse effects in
hematologic malignancies treated with chimeric antigen receptor (CAR) T
cell therapy: a systematic review and Meta-analysis. BMC Cancer.
2022;22(1):98.
9. Gagelmann N, Wulf GG, Duell J, Glass B, Heteren PV, von Tresckow B,
et al. Hematopoietic stem cell boost for persistent neutropenia after
CAR-T cell therapy: a GLA/DRST study. Blood Adv. 2022.
10.1182/bloodadvances.2022008042
10. Shahzad M, Siddiqui RS, Anwar I, Chaudhary SG, Ali T, Naseem M, et
al. Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function
after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic
Review and Meta-Analysis. Transplant Cell Ther. 2021;27(10):877.e1-.e8.
11. Mullanfiroze K, Lazareva A, Chu J, Williams L, Burridge S, M Furtado
Silva J, et al. CD34+-selected stem cell boost can safely improve
cytopenias following CAR-T therapy. Blood Adv. 2022; 6(16): 4715-4718
12. Rejeski K, Burchert A, Iacoboni G, Sesques P, Fransecky L, Buecklein
V, et al. Safety and feasibility of stem cell boost as a salvage therapy
for severe hematotoxicity after CD19 CAR T-cell therapy. Blood Adv.
2022; 6(16): 4719-4725